FDA advisory panel unanimously backs Moderna’s flu vaccine

The FDA’s Vaccines and Related Biological Products Advisory Committee voted unanimously to recommend Moderna’s seasonal influenza vaccine.

The vote overturns earlier hesitations from previous agency leadership and signals confidence in the data submitted by Moderna.

While the advisory panel’s endorsement does not constitute final approval, it is a key step toward potential licensure and could influence the company’s flu-season strategy.